Data from these studies suggest that blocking IL-1R7 could be a potential therapeutic strategy to specifically modulate IL-18 signaling and IL-18-related inflammatory diseases including MAS and possibly in patients with MAS-like clinical manifestations of COVID-19. Here, IL18RAP is linked to macrophage activation syndrome.